Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Mutations landscape of relapsed refractory multiple myeloma patients prior to anti-BCMA treatment

View Full Paper
Ask AI
Bookmark
Share

Authors

NNNour NassourSPSarah Parker

Discussion

Loading...

Member takes

Overview

Genomic sequencing reveals critical mutations influencing progression-free survival in relapsed refractory multiple myeloma patients prior to anti-BCMA therapy.

Key Points

  • This research examines the mutational landscape of relapsed refractory multiple myeloma patients before receiving anti-BCMA treatment.
  • Performed genomic sequencing focusing on 144 genes via next-generation sequencing.
  • Analyzed DNA from cryopreserved bone marrow specimens of patients prior to anti-BCMA therapy.
  • Clinical characteristics derived from medical records and a maintained database.
  • Multivariable analysis evaluated progression-free survival (PFS) and overall survival (OS).
  • Included 47 BCMA-naïve patients divided into responders and non-responders.
  • Median mutational burden was significantly higher in non-responders compared to responders.
  • Key mutations included DNMT3A and TP53, with implications for PFS and OS.

Cite This Study

Nassour et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dbf5https://doi.org/10.1182/blood-2025-7484
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma2024 · 56 citations
  2. 2Impact of prior BCMA-targeted therapy on CAR-T expansion and host T-cell phenotypes in patients with Relapsed/Refractory multiple myeloma receiving BCMA CAR-T therapy2025
  3. 3Survival outcomes of multiple myeloma patients previously exposed to BCMA-targeted therapies in the honeur european network2025
  4. 4BCMA-CART therapy in 29 cases of relapsed or refractory multiple myeloma:a retrospective study2025
  5. 5P56 | BASELINE IMMUNE PROFILE PREDICTS RESPONSE TO BISPECIFIC ANTIBODIES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD MONOCENTRIC EXPLORATORY ANALYSIS2026